In this hard-hitting episode of Global Market Bulletin TV, CEL-SCI Corporation (NYSE:CVM) CEO Geert Kersten sits down with host Leyla Gulen for an unfiltered, deep-dive interview that breaks down the latest developments surrounding Multikine®, the company’s headline-making cancer immunotherapy. Kersten opens up about the foundations on which CEL-SCI was built, the company’s decades-long mission, and what investors can expect in the critical months ahead.
Kersten walks viewers through CEL-SCI’s Phase 3 clinical trial results—one of the largest head and neck cancer immunotherapy trials ever conducted—and discusses the recent publication of these findings on ClinicalTrials.gov. He highlights a key discovery from the radiation-only arm of the trial, where 16% of patients experienced tumor shrinkage of at least 30% before undergoing surgery, with five patients achieving complete tumor regression, a result that continues to generate significant interest among oncologists.
He also shares how leading cancer specialists reacted to CEL-SCI’s data at premier medical conferences such as ESMO and ASCO, and he provides insight into how Multikine’s potential role in neoadjuvant therapy could reshape the landscape of head and neck cancer treatment.
In this Global Market Bulletin exclusive, Kersten addresses what he believes is the biggest problem—and greatest opportunity—in modern immunotherapy, and how CEL-SCI aims to solve it. He also gives investors a clear, forward-looking perspective on the company’s next 6 to 12 months, including regulatory strategy, development milestones, and the evolving market environment for immune-based oncology therapies.
About the Guest: Geert Kersten (CEO, CEL-SCI Corporation)
Geert Kersten has led CEL-SCI Corporation since 1995, guiding the company through some of the most volatile periods in biotech. A recognized pioneer in cancer immunotherapy, Kersten has spent nearly four decades shaping CEL-SCI’s scientific and strategic direction. His background spans law, finance, and biotech leadership, with earlier roles at Finley & Kumble and Source Capital. Kersten holds an MBA from George Washington University, a J.D. from American University, and is the inventor of a patent involving Multikine’s potential in cholesterol management. His passion for global health, paired with his deep industry expertise, continues to anchor CEL-SCI’s long-term vision.
CHECK THIS OUT: Why Nebius (NBIS) Could Outperform CoreWeave & Dominate the $9B AI Infrastructure Market and Is Lucid Group (LCID) Running Out of Cash? $875M Note Deal Raises Alarms.
About CEL-SCI Corporation (NYSEAMERICAN: CVM)
CEL-SCI operates one of the most ambitious and comprehensive cancer immunotherapy programs in the world. Its landmark IT-MATTERS Phase 3 clinical trial, spanning 928 patients across 23 countries, remains the largest head and neck cancer study of its kind. The trial evaluated whether Multikine, administered before standard-of-care treatment, could improve survival outcomes in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
The FDA has granted Multikine Orphan Drug designation, recognizing its potential in a critical and underserved cancer population. CEL-SCI’s rigorous clinical program adheres to international regulatory standards, including Good Clinical Practice and International Council for Harmonization guidance.
With new data, renewed scientific attention, and a growing awareness of the urgent need for better neoadjuvant cancer treatments, CEL-SCI continues to push forward on its mission to change how head and neck cancers are treated worldwide.
READ ALSO: Above Food (ABVE) to Issue 1.1 Billion New Shares in Merger and Perpetua Resources (PPTA) Soars 171% as U.S. Approves $1.3B Gold-Antimony Mine.
